Physician profile
James Tasch
NPI 1689031742
$2,954.23
in general payments reported to CMS, 2019-2025
26 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $189 · 2022: $300 · 2023: $1,070 · 2024: $656 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Education: $88.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.13 |
| Education | $88.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,195.87 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $266.28 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $192.68 | 2022-2025 | Dupixent |
| Medtronic, INC. | $149.17 | 2023 | Illumisite |
| Actelion Pharmaceuticals US, INC. | $121.84 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $109.35 | 2022-2025 | Tezspire |
| Genzyme Corporation | $109.18 | 2022-2025 | |
| Exelixis INC. | $83.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.00 | 2023-2024 | Ofev |
| Seagen INC. | $59.92 | 2022 | |
| Merck Sharp & Dohme LLC | $55.55 | 2023-2024 | Winrevair, Keytruda |
| Abbvie INC. | $54.57 | 2024-2025 | |
| Verona Pharma, INC. | $54.17 | 2025 | Ohtuvayre |
| Eisai INC. | $49.96 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $39.86 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $34.99 | 2022 | |
| Resmed Corp | $33.72 | 2023-2024 | |
| Lilly USA, LLC | $30.54 | 2025 | Zepbound |
| Pharmacyclics LLC, An Abbvie Company | $29.78 | 2023 | Imbruvica |
| Beigene USA, INC. | $29.14 | 2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $26.03 | 2023 | Opdivo |
| Sobi, INC | $24.98 | 2024 | |
| Cti Biopharma Corp. | $24.97 | 2023 | Vonjo |
| Gilead Sciences, INC. | $24.96 | 2023 | Trodelvy |
| Zoll Respicardia, INC. | $17.38 | 2025 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.